Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus

Clinical Biochemistry

Volumn 39, Issue 4, 2006, Pages 378-386

  Wilson, D ^a   Johnston, F ^b   Holt, D ^c   Moreton, M ^c   Engelmayer, J ^d   Gaulier, J M ^e   Luthe, H ^d   Marquet, P ^e   Moscato, D ^f   Oellerich, M ^d   Mosso, R ^f   Streit, F ^d   Brunet, M ^g   Fillee, C ^h   Schmid, R ⁱ   Wallemacq, P ^h   Barnes, G ^a  

^a ABBOTT LABORATORIES   (United States)

^b Axis Shield Diagnostics Ltd   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f MOLINETTE HOSPITAL   (Italy)

^g HOSPITAL CLÍNIC   (Spain)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

HPLC UV; Immunoassay; Immunosuppression; IMx; LC MS MS; MEIA; Rapamune ; Sirolimus

Indexed keywords

RAPAMYCIN;

ANALYTIC METHOD; ANTIBODY SPECIFICITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DRUG DETERMINATION; HEMATOCRIT; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL; STANDARDIZATION; VALIDATION PROCESS;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIROLIMUS; SPECTROPHOTOMETRY, ULTRAVIOLET; TANDEM MASS SPECTROMETRY;

EID: 33646088359     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.01.017     Document Type: Article

References (28)

1. Herwig-Ulf M.K., and Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentration. Clin. Ther. 22 (2002) B93-B100 (Suppl B)
2. MacDonald A., Scarola J., Burke J.T., and Zimmerman J.J. Clinical pharmacokinetics and therapeutic drug monitoring for sirolimus. Clin. Ther. 22 (2000) B101-B121 (Suppl B)
3. Holt D.W., Denny K., Lee T.D., and Johnston A. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant. Proc. Suppl. 3 (2003) A157
4. Napoli K.L., and Kahan B.D. Routine clinical monitoring of sirolimus (rapamycin) whole blood concentrations by HPLC with ultraviolet detection. Clin. Chem. 42 (1996) 1943-1948
5. D. Cattaneo, N. Perico, F. Gaspari, Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr B 774:187-94.
6. Wallemacq P., Vanbinst R., Asta S., and Cooper D.P. High-throughput liquid chromatography-tandem mass spectrophotometric analysis of sirolimus in whole blood. Clin. Chem. Lab. Med. 41 7 (2003) 921-925
7. Holt D.W., Lee T., Jones K., and Johnston A. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin. Chem. 46 (2000) 1179-1183
8. Streit F., Armstrong V.W., and Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routing method for the simultaneous determination of sirolimus, everolimus, tacrolimus and cyclosporin A in whole blood. Clin. Chem. 48 (2002) 955-958
9. Fiore M., Mitchell J., Doan T., Nelson R., Winter G., Grandone C., et al. The Abbott MEIA automated benchtop immunochemistry analyzer. Clin. Chem. 34 (1988) 1726-1732
10. Meleki S., Graves S., Becker S., Horwatt R., Hicks D., Stroshane R.M., et al. Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography. Clin. Ther. 22 (2000) B25-B38 (Suppl B)
11. Holt D.W., Lee T., and Johnston A. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. Clin. Ther. 22 (2000) B38-B48 (Suppl B)
12. Salm P., Taylor P.J., and Pillans P.I. Analytical performance of microparticle enzyme immunoassay and HPLC-tandem mass spectrometry in the determination of sirolimus in whole blood. Clin. Chem. 45 (1999) 2278-2279
13. Salm P., Taylor P.J., and Pillans P.I. The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients. Clin. Ther. 22 (2000) B71-B85 (Suppl B)
14. Jones K., Saadat-Lajevardi S., Lee T., Horwatt R., Hicks D., Johnston A., et al. An immunoassay for the measurement of sirolimus. Clin. Ther. 22 (2000) B49-B61 (Suppl B)
15. Christians U., Sattler M., Schiebel H.-M., Kruse C., Radeke H.H., Linck A., et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab. Dispos. 20 (1992) 186-191
16. Streit F., Christians U., Schiebel H.-M., Meyer A., and Sewing K.-F. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab. Dispos. 24 (1996) 1272-1278
17. Sattler M., Guengerich F.P., Yun C.-H., Christians U., and Sewing K.-F. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20 (1992) 753-761
18. Lampen A., Zhang Y., Hackbarth I., Benet L.Z., Sewing K.-F., and Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. JPET 285 (1998) 1104-1112
19. Streit F., Christians U., Sciebel H.-M., Napoli K.L., Ernst L., Linck A., et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin. Chem. 42 (1996) 1417-1425
20. National Committee for Clinical Laboratory Standards. Interference testing in clinical chemistry; approved guideline. NCCLS Document EP7-A. Wayne, PA: NCCLS; 2002.
21. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices-Approved guideline. NCCLS Document EP5-A. Wayne, PA: NCCLS; 2001.
22. Analytical Services International Ltd. (www.bioanalytics.co.uk).
23. Passing H., and Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J. Clin. Chem. Clin. Biochem. 21 (1983) 709-720
24. Wilson D.H., Johnston F., Sepe D., and Barnes G. Inter-laboratory differences in sirolimus results from six sirolimus testing centers using HPLC tandem mass spectrometry (LC/MS/MS). Clin. Chim. Acta 355 (2005) 211-213
25. Holt D.W., McKeown D.A., Lee T.D., Hicks, Cai P., and Johnston A. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. Transplant. Proc. 36 10 (2004) 3223-3225
26. Mahalati K., and Kahan B.D. Clinical pharmacokinetics of sirolimus. Clin. Pharmacokinet. 40 8 (2001) 573-585
27. Shaw L.M., Kaplan B., and Brayman K.L. Introduction and overview-Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Clin. Ther. 22 (2000) B1-B13
28. P.J. Taylor, A.G. Johnson, Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B; 718 (2), 251-7.